Press Releases
SINGAPORE, JANUARY 12, 2023: Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences® (Caris)’ molecular profiling services in South East Asia. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. The company’s … Read more
Read More
Lugano, Switzerland, September 1, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, announced today the signing of an exclusive distribution license and … Read more
Read More
Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
Read More
$600 million USD acquisition will see Juniper Biologics offer the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa.
Read More
Helsinn Healthcare SA announced the signing of exclusive distribution, license and supply agreements for Aloxi®, Onicit®, Paloxi®, Akynzeo® (IV and oral formulations) and anamorelin (INN).
Read More
Juniper Biologics has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.
Read More